References
1a
Gregory RJH.
Chem. Rev.
1999,
99:
3649
1b
North M.
Tetrahedron: Asymmetry
2003,
14:
147
1c
Brunel JM.
Holmes IP.
Angew. Chem. Int. Ed.
2004,
43:
2752
2
Hanefeld U.
Org. Biomol. Chem.
2003,
1:
2405
3a
Kanerva LT.
Rahiala K.
Sundholm O.
Biocatalysis
1994,
10:
169
3b
Paizs C.
Toºa M.
Majdik C.
Tähtinen P.
Irimie FD.
Kanerva LT.
Tetrahedron: Asymmetry
2003,
14:
619
3c
Paizs C.
Tähtinen P.
Lundell K.
Poppe L.
Irimie FD.
Kanerva LT.
Tetrahedron: Asymmetry
2003,
14:
1895
3d
Paizs C.
Tähtinen P.
Toºa M.
Majdik C.
Irimie FD.
Kanerva LT.
Tetrahedron
2004,
60:
10533
4a
Effenberger F.
Förster S.
Wajant H.
Curr. Opin. Biotechnol.
2000,
11:
532
4b
Griengl H.
Schwab H.
Fechter M.
Trends Biotechnol.
2000,
18:
252
4c
Sukumaran J.
Hanefeld U.
Chem. Soc. Rev.
2005,
34:
530
5a
Inagaki M.
Hiratake J.
Nishioka T.
Oda J.
J. Am. Chem. Soc.
1991,
113:
9360
5b
Inagaki M.
Hiratake J.
Nishioka T.
Oda J.
J. Org. Chem.
1992,
57:
5643
5c
Inagaki M.
Hatanaka A.
Mimura M.
Hiratake J.
Nishioka T.
Oda J.
Bull. Chem. Soc. Jpn.
1992,
65:
111
6a
Veum L.
Hanefeld U.
Tetrahedron: Asymmetry
2004,
15:
3707
6b
Veum L.
Kanerva LT.
Halling PJ.
Maschmeyer T.
Hanefeld U.
Adv. Synth. Catal.
2005,
347:
1015
7a
Ryu DH.
Corey EJ.
J. Am. Chem. Soc.
2004,
126:
8106
7b
Chang CW.
Yang CT.
Hwang CD.
Uang BJ.
Chem. Commun.
2002,
54
7c
Belokon YN.
Carta P.
North M.
Lett. Org. Chem.
2004,
1:
81
8 For the procedure see the analytical scale experiment in ref. 6b.
9a
Li Y.-X.
Straathof AJJ.
Hanefeld U.
Tetrahedron: Asymmetry
2002,
13:
739
9b
Veum L.
Kuster M.
Telalovic S.
Hanefeld U.
Maschmeyer T.
Eur. J. Org. Chem.
2002,
1516
9c
Hanefeld U.
Li Y.
Sheldon RA.
Maschmeyer T.
Synlett
2000,
1775
10 All conversion and enantiomeric purity was determined by chiral GC using a β-cyclodextrin column (CP-Chirasil-Dex CB 25m × 0.25 mm) using He with a linear gas velocity of 75 cm/s.
11 Racemic 3c: 1H NMR (300 MHz, CDCl3): δ = 0.89 (t, J = 7.0 Hz, 3 H, CH
3-CH2), 1.25-1.40 (m, 8 H, CH3-CH
2-CH
2-CH
2-CH
2), 1.50 (m, 2 H, CH
2-CH2-CH), 1.90 (m, 2 H, CH
2-CH), 2.13 (s, 3 H, CH
3-C=O), 5.31 (t, J = 6.8 Hz, 1 H, CH-CN). 13C NMR (75 MHz, CDCl3): δ = 14.0 (C8), 20.4 (CH3-C=O), 22.6 (C7), 24.6 (C6), 28.8 (C5), 29.0 (C4), 31.6 (C3), 32.3 (C2), 61.2 (C-O), 117.0 (CN), 169.2 (C=O).
Racemic 3d: 1H NMR (300 MHz, CDCl3): δ = 0.88 (t, J = 6.8 Hz, 3 H, CH
3-CH2), 1.20-1.40 (m, 10 H, CH3-CH
2-CH
2-CH
2-CH
2-CH
2), 1.50 (m, 2 H, CH
2-CH2-CH), 1.90 (m, 2 H, CH
2-CH), 2.12 (s, 3 H, CH
3-CO), 5.30 (t, J = 6.8 Hz, 1 H, CH-CN). 13C NMR (75 MHz, CDCl3): δ = 14.1 (C10), 20.4 (CH3-C=O), 22.7 (C9), 24.6 (C8), 28.9 (C7), 29.3 (C6), 29.3 (C5), 29.4 (C4), 31.9 (C3), 32.3 (C2), 61.2 (C-O), 117.0 (CN), 169.2 (C=O).
12 For the procedure, see the preparative scale experiment in ref. 6b.
13 Compound (S)-3a: [α]D
25 -47,7 (c 1, MeOH). 1H NMR (300 MHz, CDCl3): δ = 1.10-1.40 (m, 5 H, ring CH and CH2), 1.70-1.90 (m, 6 H, ring CH2), 2.14 (s, 3 H, CH
3), 5.17 (d, J = 6.0 Hz, 1 H, CH-CN). 13C NMR (75 MHz, CDCl3): δ = 20.3 (CH3), 25.3, 25.4, 25.8, 28.0, 28.1 and 40.5 (ring C), 65.6 (CH-O), 116.2 (CN), 169.3 (C=O).
14 Compound (S)-3b: [α]D
25 -36.9 (c 1, MeOH). 1H NMR (400 MHz, CDCl3): δ = 0.90 (m, 3 H, CH
3-CH2), 1.33 (m, 4 H, CH3-CH
2-CH
2), 1.50 (m, 2 H, CH
2-CH2-CH), 1.90 (m, 2 H, CH
2-CH), 2.14 (s, 3 H, CH
3-CO), 5.31 (t, J = 6.8 Hz, 1 H, CH-CN). 13C NMR (100 MHz, CDCl3): δ = 13.9 (C6), 20.4 (CH3-C=O), 22.3 (C5), 24.2 (C4), 30.9 (C3), 32.3 (C2), 61.2 (CH), 117.0 (CN), 169.2 (C=O).